10.1371/journal.pone.0081234PLoS ONE812-POLN

A Hurria

A Minisini

AA Argyriou

AH Miller

AL Marsland

Alexandre Chan

AM Shapiro

B Seruga

BN Lee

C Schubert

C Sioka

CA Meyers

CC Reyes-Gibby

CD Aluise

CJ Malkin

CJ Wilson

CL Raison

CR De Almodovar

DC Anthony

DC Lee

DD Correa

EA Walker

F Munir

G Joshi

G Kenis

G Winocur

GE Lash

Gianluigi Forloni

H Knobel

Han Kiat Ho

HK Gan

HSL Jim

J Licinio

J McAfoose

J Pfeilschifter

J Tangpong

J Vardy

J Wei

JA O'Shaughnessy

JF Deeken

JJ Foley

JJ Pilcher

JM Long

JP Konsman

JS Myers

JS Wefel

K Hager

K Vandenbroeck

L Pusztai

LA Christie

LI Wagner

M Cibelli

M Corsi-Cabrera

MA Lynch

MC Janelsins

ME McCarthy

MH Antoni

MJJ Pullens

MM Madeleine

MP Purdue

MT Knobf

N Boykoff

N Rothman

N Sachdeva

NC DuPont

NC Dupont

O Beauchet

PA Ganz

PJ Fray

PK Peterson

R Seigers

RB Raffa

RJ Dunlop

RM Reitan

S Das

S Kesler

S Yennurajalingam

SA Reid-Arndt

SB Schagen

Si Rong Lim

SS Khan

SX Leng

T Rich

TA Ahles

TC Unfer

WA Banks

Yin Ting Cheung

YT Cheung

Z Kronfol

PubMed

ObjectivesWhile various clinical and pharmacological determinants for chemotherapy-associated cognitive impairment have been identified, conflicting evidence suggests that cytokines might play an intermediary role. The objective of this systematic review was to evaluate the current evidence pertaining to the associations among chemotherapy, cytokines induction and cognitive impairment in cancer patients.MethodsA literature search with PubMed and SciVerse Scopus was conducted in March 2013 to gather relevant articles and abstracts that fulfilled the inclusion and exclusion criteria. This review included studies that had performed objective and/or subjective cognitive assessments and cytokine measurements on defined populations of cancer patients who received chemotherapy.ResultsHigh methodological heterogeneity existed among the selected studies which differed in cancer populations, subject characteristics, cognitive endpoints, types of cytokines tested and their measurement methods. Weak to moderate correlations were observed between IL-1β, IL-6, TNF-α levels, and different degrees of cognitive impairment. Different types of chemotherapy treatments might lead to varying presentations and severities of cytokine-induced cognitive impairment. Notably, the time concordance between the onset of cytokine induction and occurrence of cognitive impairment was not well elucidated. A number of confounding factors was identified to interfere with the expression levels of cytokines; these confounders included subjects' cancer types, ages, genders, genetics and psychosocial characteristics such as anxiety, depression and fatigue.ConclusionAlthough existing studies observed cognitive impairment and cytokine dysregulation in patients who receive chemotherapy, our results suggest that the intermediary role of cytokines in post-chemotherapy cognitive impairment is still controversial and requires further evaluation. A list of methodological recommendations is proposed to harmonize future studies of this subject matter

Directory of Open Access Journals

PLoS ONE

Cytokines as mediators of chemotherapy-associated cognitive changes: current evidence, limitations and directions for future research.

Crossref

Cytokines as Mediators of Chemotherapy-Associated Cognitive Changes: Current Evidence, Limitations and Directions for Future Research

Cheung, Yin Ting

Lim, Si Rong

Ho, Han Kiat

Chan, Alexandre

eScholarship - University of California

Objectives: While various clinical and pharmacological determinants for chemotherapy-associated cognitive impairment have been identified, conflicting evidence suggests that cytokines might play an intermediary role. The objective of this systematic review was to evaluate the current evidence pertaining to the associations among chemotherapy, cytokines induction and cognitive impairment in cancer patients. Methods: A literature search with PubMed and SciVerse Scopus was conducted in March 2013 to gather relevant articles and abstracts that fulfilled the inclusion and exclusion criteria. This review included studies that had performed objective and/or subjective cognitive assessments and cytokine measurements on defined populations of cancer patients who received chemotherapy. Results: High methodological heterogeneity existed among the selected studies which differed in cancer populations, subject characteristics, cognitive endpoints, types of cytokines tested and their measurement methods. Weak to moderate correlations were observed between IL-1b, IL-6, TNF-a levels, and different degrees of cognitive impairment. Different types of chemotherapy treatments might lead to varying presentations and severities of cytokine-induced cognitive impairment. Notably, the time concordance between the onset of cytokine induction and occurrence of cognitive impairment was not well elucidated. A number of confounding factors was identified to interfere with the expression levels of cytokines; thes

Re Chan

CiteSeerX

Cytokines as mediators of chemotherapyassociated cognitive changes: current evidence, limitations and directions for future research

<div>ObjectivesWhile various clinical and pharmacological determinants for chemotherapy-associated cognitive impairment have been identified, conflicting evidence suggests that cytokines might play an intermediary role. The objective of this systematic review was to evaluate the current evidence pertaining to the associations among chemotherapy, cytokines induction and cognitive impairment in cancer patients.MethodsA literature search with PubMed and SciVerse Scopus was conducted in March 2013 to gather relevant articles and abstracts that fulfilled the inclusion and exclusion criteria. This review included studies that had performed objective and/or subjective cognitive assessments and cytokine measurements on defined populations of cancer patients who received chemotherapy.ResultsHigh methodological heterogeneity existed among the selected studies which differed in cancer populations, subject characteristics, cognitive endpoints, types of cytokines tested and their measurement methods. Weak to moderate correlations were observed between IL-1β, IL-6, TNF-α levels, and different degrees of cognitive impairment. Different types of chemotherapy treatments might lead to varying presentations and severities of cytokine-induced cognitive impairment. Notably, the time concordance between the onset of cytokine induction and occurrence of cognitive impairment was not well elucidated. A number of confounding factors was identified to interfere with the expression levels of cytokines; these confounders included subjects' cancer types, ages, genders, genetics and psychosocial characteristics such as anxiety, depression and fatigue.ConclusionAlthough existing studies observed cognitive impairment and cytokine dysregulation in patients who receive chemotherapy, our results suggest that the intermediary role of cytokines in post-chemotherapy cognitive impairment is still controversial and requires further evaluation. A list of methodological recommendations is proposed to harmonize future studies of this subject matter.</div

Yin Ting Cheung (493507)

Si Rong Lim (493508)

Han Kiat Ho (493509)

Alexandre Chan (493510)

The Francis Crick Institute

While various clinical and pharmacological determinants for chemotherapy-associated cognitive impairment have been identified, conflicting evidence suggests that cytokines might play an intermediary role. The objective of this systematic review was to evaluate the current evidence pertaining to the associations among chemotherapy, cytokines induction and cognitive impairment in cancer patients.A literature search with PubMed and SciVerse Scopus was conducted in March 2013 to gather relevant articles and abstracts that fulfilled the inclusion and exclusion criteria. This review included studies that had performed objective and/or subjective cognitive assessments and cytokine measurements on defined populations of cancer patients who received chemotherapy.High methodological heterogeneity existed among the selected studies which differed in cancer populations, subject characteristics, cognitive endpoints, types of cytokines tested and their measurement methods. Weak to moderate correlations were observed between IL-1β, IL-6, TNF-α levels, and different degrees of cognitive impairment. Different types of chemotherapy treatments might lead to varying presentations and severities of cytokine-induced cognitive impairment. Notably, the time concordance between the onset of cytokine induction and occurrence of cognitive impairment was not well elucidated. A number of confounding factors was identified to interfere with the expression levels of cytokines; these confounders included subjects' cancer types, ages, genders, genetics and psychosocial characteristics such as anxiety, depression and fatigue.Although existing studies observed cognitive impairment and cytokine dysregulation in patients who receive chemotherapy, our results suggest that the intermediary role of cytokines in post-chemotherapy cognitive impairment is still controversial and requires further evaluation. A list of methodological recommendations is proposed to harmonize future studies of this subject matter

Cheung Yin Ting

Lim Si Rong

Ho Han Kiat

Chan Alexandre

Public Library of Science (PLOS)

http://dx.doi.org/10.1371/journal.pone.0081234

Cytokines as mediators of chemotherapy-associated cognitive changes: Current evidence, limitations and directions for future research

Cytokines as mediators of chemotherapy-associated cognitive changes: Current evidence, limitations and directions for future research

Abstract

Similar works

Full text

Available Versions